OBJECTIVES: Colorectal cancer (CRC) is a feared complication of chronic ulcerative colitis (UC). Annual endoscopic surveillance is recommended for the detection of early neoplasia. 5-Aminosalicylates (5-ASAs) may prevent some UC-associated CRC. Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs. METHODS: We performed systematic reviews of the literature, and created a Markov computer model simulating a cohort of 35-year-old men with chronic UC, followed until the age of 90 years. Twenty-two strategies were modeled: natural history (no 5-ASA or surveillance), surveillance without 5-ASA at intervals of 1-10 years, 5-ASA plus surveillance every 1-10 years, and 5-ASA alone. The primary outcome was the ideal interval of surveillance in the setting of 5-ASA maintenance, assuming a third-party payer was willing to pay $100,000 for each quality-adjusted life-year (QALY) gained. RESULTS: In the natural history strategy, the CRC incidence was 30%. Without 5-ASA, annual surveillance was the ideal strategy, preventing 89% of CRC and costing $69,100 per QALY gained compared with surveillance every 2 years. 5-ASA alone prevented 49% of CRC. In the setting of 5-ASA, surveillance every 3 years was ideal, preventing 87% of CRC. 5-ASA with surveillance every 2 years cost an additional $147,500 per QALY gained, and 5-ASA with annual surveillance cost nearly $1 million additional per QALY gained compared with every 2 years. In Monte Carlo simulations, surveillance every 2 years or less often was ideal in 95% of simulations. CONCLUSIONS: If 5-ASA is efficacious chemoprevention for UC-associated CRC, endoscopic surveillance might be safely performed every 2 years or less often. Such practice could decrease burdens to patients and on endoscopic resources with a minimal decrease in quality-adjusted length of life, because 5-ASA with annual surveillance may cost nearly $1 million per additional QALY gained.
OBJECTIVES:Colorectal cancer (CRC) is a feared complication of chronic ulcerative colitis (UC). Annual endoscopic surveillance is recommended for the detection of early neoplasia. 5-Aminosalicylates (5-ASAs) may prevent some UC-associated CRC. Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs. METHODS: We performed systematic reviews of the literature, and created a Markov computer model simulating a cohort of 35-year-old men with chronic UC, followed until the age of 90 years. Twenty-two strategies were modeled: natural history (no 5-ASA or surveillance), surveillance without 5-ASA at intervals of 1-10 years, 5-ASA plus surveillance every 1-10 years, and 5-ASA alone. The primary outcome was the ideal interval of surveillance in the setting of 5-ASA maintenance, assuming a third-party payer was willing to pay $100,000 for each quality-adjusted life-year (QALY) gained. RESULTS: In the natural history strategy, the CRC incidence was 30%. Without 5-ASA, annual surveillance was the ideal strategy, preventing 89% of CRC and costing $69,100 per QALY gained compared with surveillance every 2 years. 5-ASA alone prevented 49% of CRC. In the setting of 5-ASA, surveillance every 3 years was ideal, preventing 87% of CRC. 5-ASA with surveillance every 2 years cost an additional $147,500 per QALY gained, and 5-ASA with annual surveillance cost nearly $1 million additional per QALY gained compared with every 2 years. In Monte Carlo simulations, surveillance every 2 years or less often was ideal in 95% of simulations. CONCLUSIONS: If 5-ASA is efficacious chemoprevention for UC-associated CRC, endoscopic surveillance might be safely performed every 2 years or less often. Such practice could decrease burdens to patients and on endoscopic resources with a minimal decrease in quality-adjusted length of life, because 5-ASA with annual surveillance may cost nearly $1 million per additional QALY gained.
Authors: A J Muir; L J Edwards; L L Sanders; R R Bollinger; M J Koruda; D R Bachwich; D Provenzale Journal: Am J Gastroenterol Date: 2001-05 Impact factor: 10.864
Authors: A Reinacher-Schick; F Seidensticker; S Petrasch; M Reiser; S Philippou; D Theegarten; G Freitag; W Schmiegel Journal: Endoscopy Date: 2000-03 Impact factor: 10.093
Authors: W E Longo; K S Virgo; F E Johnson; C A Oprian; A M Vernava; T P Wade; M A Phelan; W G Henderson; J Daley; S F Khuri Journal: Dis Colon Rectum Date: 2000-01 Impact factor: 4.585
Authors: Brennan M R Spiegel; Wayne Ho; Eric Esrailian; Stephan Targan; Peter D R Higgins; Corey A Siegel; Marla Dubinsky; Gil Y Melmed Journal: Clin Gastroenterol Hepatol Date: 2008-09-04 Impact factor: 11.382
Authors: Gauree Gupta Konijeti; Mark G Shrime; Ashwin N Ananthakrishnan; Andrew T Chan Journal: Gastrointest Endosc Date: 2013-11-18 Impact factor: 9.427
Authors: Siddharth Singh; James A Proudfoot; Parambir S Dulai; Vipul Jairath; Mathurin Fumery; Ronghui Xu; Brian G Feagan; William J Sandborn Journal: Am J Gastroenterol Date: 2018-06-21 Impact factor: 10.864
Authors: Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones Journal: Can J Gastroenterol Hepatol Date: 2014-05
Authors: John B Kisiel; Gauree G Konijeti; Andrew J Piscitello; Tarun Chandra; Thomas F Goss; David A Ahlquist; Francis A Farraye; Ashwin N Ananthakrishnan Journal: Clin Gastroenterol Hepatol Date: 2016-07-25 Impact factor: 11.382
Authors: J B Kisiel; T C Yab; F T Nazer Hussain; W R Taylor; M M Garrity-Park; W J Sandborn; E V Loftus; B G Wolff; T C Smyrk; S H Itzkowitz; D T Rubin; H Zou; D W Mahoney; D A Ahlquist Journal: Aliment Pharmacol Ther Date: 2013-01-24 Impact factor: 8.171